C4X Discovery Holdings plc
(“C4XD”, “C4X Discovery” or the “Company”)
C4XD presents data on its lead addiction programme: Orexin-1 antagonist
Programme demonstrates potential application across a broad range of substance use disorders
13 November 2017 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, presented new pre-clinical data on its Orexin-1 antagonist programme at Neuroscience 2017 on 11th November 2017 in Washington, DC.
C4XD’s lead programme, Orexin-1, aims to treat addiction by targeting the “craving” process itself and, therefore, can be applied across a broad range of substance use disorders. Of particular note, C4XD announced new efficacy data of its lead compound, C4X_3256, in in vivo models of nicotine self-administration and cue-induced reinstatement. This supports the development of this compound as a therapy across two distinct areas of nicotine abuse; smoking cessation and relapse in smokers.
Clive Dix, Chief Executive Officer of C4XD, said: “This set of studies strengthens C4XD’s pre-clinical data package for our lead Orexin-1 antagonist programme. We strongly believe that the programme presents a compelling commercial case for partnership due to its broad applicability to substance use as well as related disorders, such as anxiety, post-traumatic stress disorder, and impulse control. This is supported by the high level of pre-clinical partnering interest received that have enabled us to enter late-stage commercial discussions.”
Data presentation details:
Title: Efficacy of a novel selective oral Orexin 1 receptor antagonist in rat models of nicotine self-administration and reinstatement
Authors: C. Murray, G. A. Higgins, B. P. Martin, T. Nowak, J. C. Fox;
C4X Discovery, Manchester, United Kingdom; Intervivo Solutions Inc, Toronto, ON, Canada
To view the full abstract, please follow this link.